文献速递头颈部肿瘤放疗

调强质子治疗与容积调强弧形治疗在鼻咽癌患者中的比较:一项长期多中心队列研究

Intensity-modulated proton therapy versus volumetric-modulated ARC therapy in patients with nasopharyngeal carcinoma: A long-term, multicenter cohort study.
PubMed 文献 · Radiother Oncol · 2024-11-23

本研究基于长庚研究数据库分析2016至2021年接受根治性放疗的鼻咽癌患者,按分期、诊断年份和年龄(±10岁)1:1匹配后比较调强质子治疗(IMPT)与容积调强弧形治疗(VMAT)。匹配后IMPT与全因死亡(aHR 0.31,95%CI 0.15-0.62)和疾病复发(aHR 0.58,95%CI 0.34-0.99)改善相关,并降低喂食管置入发生率(aHR 0.31,95%CI 0.18-0.55)。作者结论认为IMPT与更好的总生存和更低的吞咽困难发生率相关,需进一步随机试验确认。

要点

  • 匹配后IMPT组全因死亡aHR 0.31(95%CI 0.15-0.62),优于VMAT组。
  • 匹配后IMPT组疾病复发aHR 0.58(95%CI 0.34-0.99),但敏感性分析中该显著性不一致。
  • 匹配后IMPT组喂食管置入aHR 0.31(95%CI 0.18-0.55),低于VMAT组。

核心结论

  • 作者结论认为,在鼻咽癌患者中,与VMAT相比,IMPT与显著更好的总生存结局和更低的吞咽困难发生率相关。
  • 作者指出需要进一步随机试验来确认这些发现。

研究设计与样本

  • 本研究为长期多中心队列研究,数据来自长庚研究数据库。
  • 分析纳入2016至2021年接受根治性放疗(IMPT或VMAT)的鼻咽癌患者,排除远处转移或同时合并其他恶性肿瘤者。
  • 按分期、诊断年份和年龄(±10岁)进行1:1匹配,采用Cox比例风险模型评估肿瘤学结局和毒性。
  • 敏感性分析采用逆概率治疗加权和额外的1:2匹配。
  • 从1202例鼻咽癌患者队列中,从接受IMPT的294例亚组中选取276例,与等量接受VMAT的患者匹配。

主要发现

  • 匹配后IMPT与改善的肿瘤学结局相关,全因死亡aHR 0.31(95%CI 0.15-0.62)。
  • 匹配后IMPT与疾病复发aHR 0.58(95%CI 0.34-0.99)相关。
  • 匹配后IMPT与喂食管置入发生率降低相关,aHR 0.31(95%CI 0.18-0.55)。
  • 竞争风险和敏感性分析支持上述趋势,但疾病复发的显著性不一致。

局限性

  • 作者指出需要进一步随机试验来确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Data evaluating the impact of intensity-modulated proton therapy (IMPT) on survival among nasopharyngeal carcinoma (NPC) patients are limited. This study aims to elucidate the survival benefits and toxicity profiles of IMPT compared to modern photon therapy, volumetric-modulated arc therapy (VMAT), over an extended follow-up period. METHODS: We analyzed data from NPC patients recorded in the Chang Gung Research Database. This analysis focused on individuals who received definitive radiotherapy, either IMPT or VMAT therapy, from 2016 to 2021. Patients with distant metastasis or concurrent other malignancies were excluded. We performed 1:1 matching based on stage, year of diagnosis, and age (± 10 years). Oncological outcomes and toxicities were assessed using Cox proportional hazards modeling. For sensitivity analysis, we employed inverse probability of treatment weighting and additional 1:2 matching. RESULTS: Out of a 1,202 NPC patients' cohort, 276 were selected from a subset of 294 who received IMPT and matched with an equivalent number of patients receiving VMAT. IMPT was associated with improved oncological outcomes after matching, with an adjusted hazard ratio (aHR) of 0.31 (95% CI: 0.15-0.62) for all-cause mortality and an aHR of 0.58 (95% CI: 0.34-0.99) for disease recurrence. Additionally, IMPT was linked to a reduced incidence of feeding tube placement, with an aHR of 0.31 (95% CI: 0.18-0.55). Competing risk and sensitivity analyses corroborated these trends, though the significance for disease recurrence was not consistent. CONCLUSION: IMPT was associated with significantly better overall survival outcomes and a lower incidence of dysphagia compared to VMAT in NPC patients. Further randomized trials are needed to confirm these findings.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Wu CN, Wang JD, Chen WC, et al. Intensity-modulated proton therapy versus volumetric-modulated ARC therapy in patients with nasopharyngeal carcinoma: A long-term, multicenter cohort study. Radiother Oncol. 2024. PMID: 39586359. doi:10.1016/j.radonc.2024.110648

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。